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Non-alcoholic fatty liver disease (NAFLD), specifically its progressive form non-alcoholic steatohe-
patitis (NASH), represents the fastest growing indication for liver transplantation in Western
countries. Diabetes mellitus, morbid obesity and cardiovascular disease are frequently present in
patients with NAFLD who are candidates for liver transplantation. These factors require specific
evaluation, including a detailed pre-surgical risk stratification, in order to improve outcomes after
liver transplantation. Moreover, in the post-transplantation setting, the incidence of cardiovascular
events and metabolic complications can be amplified by immunosuppressive therapy, which is a
well-known driver of metabolic alterations. Indeed, patients with NASH are more prone to devel-
oping early post-transplant complications and, in the long-term, de novo malignancy and cardio-
vascular events, corresponding to higher mortality rates. Therefore, a tailored multidisciplinary
approach is required for these patients, both before and after liver transplantation. Appropriate
candidate selection, lifestyle modifications and specific assessment in the pre-transplant setting, as
well as pharmacological strategies, adjustment of immunosuppression and a healthy lifestyle in the
post-transplant setting, play a key role in correct management.
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Non-alcoholic fatty liver disease (NAFLD) is a
pathological condition, which ranges from simple
steatosis (NAFL) to non-alcoholic steatohepatitis
(NASH) and cirrhosis. The liver is primarily
involved – however, systemic metabolic complica-
tions are often present in patients with NAFLD.1
Recently the term metabolic dysfunction-
associated fatty liver disease (MAFLD) has been
proposed to better describe liver disease associated
with metabolic dysfunction,2 leading to discussions
within the scientific community regarding poten-
tial consequent changes in diagnosis, clinical
management and drug development.3–5
Until now, NAFLD has been diagnosed by the
presence of hepatic steatosis on radiological im-
aging or biopsy, after ruling out all other reason-
able causes (e.g. alcohol consumption). Conversely,
the diagnosis of NASH requires identification
of 3 pathognomonic features on liver biopsy:
ballooning, lobular inflammation and steatosis.6
Differentiating NASH from NAFLD is paramount
for determining the prognosis of liver disease. Pa-
tients affected by NASH are at risk of worsening
outcomes, such as end-stage liver disease (ESLD)
and hepatocellular carcinoma (HCC). It is estimated
that 20% of patients with NASH develop cirrhosis,
whereas the risk of HCC in patients with NASH
increased 7.7-fold between 2002–2016, from 2.1%
to 16.2%.7 Since the prevalence rates of NAFLD inpatients with diabetes mellitus (DM) and morbid
obesity are nearly 58%8 and 30%,9 respectively, the
correct assessment of these metabolic diseases and
their complications is relevant in liver transplant
(LT) candidates as well as in the post-LT period.
However, controversial data still exist
regarding strategies for optimal candidate evalu-
ation before LT and optimal management of
metabolic complications after LT. Therefore, the
aim of this manuscript is to highlight available
scientific evidence on the management of pa-
tients with NAFLD before and after LT, focusing
on the assessment and treatment of cardio-
metabolic complications.Epidemiology and natural history of
NAFLD in the LT setting
Before liver transplantation
According to data from the European Liver
Transplant Registry (ELTR) and the United
Network for Organ Sharing (UNOS) databases,
NAFLD/NASH has been the fastest growing indi-
cation for LT in the last 20 years.10,11 It is the
second leading indication for LT among adults in
the United States, with 1,321 (21.5%) LTs per-
formed in 2018,10 and a similar increase has been
seen in Europe, with NAFLD-related cirrhosis ac-
counting for 1.2% of LTs in 2002 compared to 8.4%
in 2016.11 However, despite the significant
Key points
 Non-alcoholic steatohepatitis (NASH) is the fastest growing indication
for liver transplantation with consequences for pre- and post-
transplant management.
 Diabetes mellitus, obesity and cardiovascular disease are frequent in
patients with NAFLD/NASH; these comorbidities require specific
assessment and treatment in the pre-liver transplant setting to avoid
unacceptably risky surgery.
 Patients with NAFLD/NASH are at higher risk of metabolic complica-
tions after liver transplantation, which can be exacerbated by immu-
nosuppressive therapy, and require specialised management.
 Lifestyle modifications, modulation of immunosuppressive therapy and
specific medical treatment of these metabolic conditions represent the
key points for post-liver transplant management.
Reviewincrease over recent years in Europe, the prevalence remains
lower than in the United States.
Similarly, NAFLD/NASH is considered the fastest growing
cause of HCC in both Europe and the United States.7 In a recent
modelling study, France is predicted to have the largest increase
in incident HCC cases (117%), and the UK the smallest (88%).
Similarly, in the United States the incidence of NAFLD/NASH-
related HCC has been estimated to increase by 137% between
2015 and 2030.12
Several factors favour the development of HCC in the context
of NAFLD/NASH, including genetic polymorphisms (i.e. PNPLA3
and TM6SF2) and environmental modifiers such as sedentary
lifestyle and high-caloric intake, which lead to obesity and in-
sulin resistance.13
Usually patients with NASH and HCC are older, have large
tumours, and are sometimes difficult to screen with ultrasound
because of obesity.14 Moreover, non-cirrhotic patients with
NAFLD/NASH are usually not included in screening programme15
and are therefore often diagnosed late. It is estimated that only
15% of patients with HCC and NAFLD/NASH are diagnosed at
Barcelona Clinic for Liver Cancer (BCLC) stages 0 or A, which
would enable a curative approach to the neoplastic disease.13
Considering indications for LT, in the European cohort of ELTR,
among a total of 68,950 LT recipients, 4% were transplanted for
NASH, of whom 39.1% had HCC.16 In the United States, this
indication is currently identified as the most rapidly growing
cause of HCC among patients on the waiting list, increasing from
2.1% in 2002 to 16.2% in 2016; p <0.0001.7 Indeed, while the
proportions of HCC related to HCV or alcohol-related liver dis-
ease remained stable, the proportion of HCC related to NAFLD/
NASH increased 7.7 fold.7 Although attention has been paid to
the potentially higher risk of death or drop-out in these patients
while they are on the waiting list for LT,17 recent data seem to
suggest that they are not disadvantaged in terms of waiting list
removal or lower transplantation rates.18
After liver transplantation
After LT, patients with NAFLD are more prone to develop peri-
surgical complications such as infections,19 whereas in the
long-term, they have a higher incidence of malignancies (33%)
and cardiovascular events (24%) compared to patients trans-
planted for other reasons.20 However, the incidence of major
complications was similar in patients with NAFLD/NASH-related
or non-NAFLD/NASH indications, as were patient and graft sur-
vival,19 with 1- and 5-year survival rates of 85%–90% and 70%–
80% reported, respectively.21 Despite these encouraging data, a
recent American study reported a lower 1-year survival rate for
NAFLD/NASH recipients compared to patients transplanted for
HCV or alcohol-related liver disease, showing that the higher risk
of death was mainly due to cardiovascular or cerebrovascular
disease.22
Considering all the metabolic complications potentially
affecting patients after LT, the risk of developing post-transplant
NAFLD/NASH can be considered high, although studies published
on this topic are based on small sample sizes, with heteroge-
neous definitions of disease recurrence.23 In a meta-analysis, the
mean 1-, 3-, and 5-year incidence rates of recurrent and de novo
NAFLD were 59%, 57%, 82% and 67%, 40%, 78%, respectively.
Conversely, the incidence of post-transplant NASH was signifi-
cantly higher when considering recurrent NASH (53%, 57.4%, and
38% at 1, 3, 5 years after LT, respectively) compared with de novo
NASH (13%, 16%, and 17%, respectively).23 Regarding advancedJHEP Reports 2020liver disease, the reported rates of cirrhosis in patients with
recurrent or de novo NAFLD are around 11%–14% and 1% at 5
years post-LT, respectively.23
Post-transplant high BMI, post-transplant hyperlipidaemia,
and a history of alcohol abuse are considered predictors of post-
LT graft steatosis.23 Nevertheless, although allograft steatosis is
extremely frequent, it does not seem to impact severely on post-
LT outcomes.24 Conversely, the effect of histologically proven
NASH on post-LT outcomes might be different from simple
steatosis, representing a strong predictor of lower long-term
survival.25 Moreover, data on re-LT outcomes in patients with
NASH seem to suggest lower survival rates at 5-years after re-LT
when compared to other aetiologies.26
Despite these data highlighting the importance of the early
diagnosis of NAFLD/NASH post-LT, it is still unclear if this pop-
ulation needs specific follow-up, in terms of frequency and type
of screening, to detect recurrent and de novo NAFLD/NASH early.
Standard biochemical liver tests and imaging techniques, such as
transient elastography27 or magnetic resonance elastography,28
are used to monitor patients at risk after LT.
In patients with HCC developed on NAFLD/NASH-related
cirrhosis, post-LT patient and graft survival rates are compara-
ble to those of other disease indications, as recently reported by a
study based on the ELTR.16 Similarly, post-transplant tumour
recurrence rates have been shown to be similar between NASH
and non-NASH aetiologies.29Metabolic complications
Diabetes mellitus
Pre-LT DM is often associated with liver diseases, such as HCV or
NAFLD, with a prevalence of 33%–66% amongst patients with
NAFLD.30 Patients with pre-LT DM are at higher risk of post-LT
infections, cardiovascular complications and longer hospital
stays,31 and present reduced long-term graft and overall sur-
vival.32 Two distinct mechanisms seem to be responsible for the
development of DM in patients with chronic liver disease.33 The
first is related to the impairment of insulin secretion or sensi-
tivity due to a specific aetiological agent, such as HCV, alcohol or
NAFLD. This condition can develop even before the development
of cirrhosis, especially in patients presenting well-known risk
factors for DM. The second, the so-called hepatogenous DM, is
strictly related to pancreatic beta-cell dysfunction, which is
proportional to liver disease severity and loss of liver function.33
Although the pathophysiological mechanisms underlying
regression of hepatogenous diabetes are largely unknown, beta-
cell restoration seems to play a central role.34 In this view,2vol. 2 j 100192
hepatogenous diabetes might benefit from LT. It is important to
assess glycaemia in all potential LT candidates and to optimise
the management of patients who show unsatisfactory glycaemic
control.10
Oral glucose tolerance test is considered the gold standard for
the diagnosis of type 2 DM; when glycated haemoglobin (HbA1c)
is used it needs to be associated with continuous blood glucose
monitoring, since HbA1c may be falsely low due to splenomegaly
and anaemia, which are frequent conditions in patients with
ESLD.33
Several issues need to be taken into account when consid-
ering pharmacological treatment of pre-LT DM, such as the
development of side effects, the risk of hypoglycaemia, and po-
tential limitations due to the presence of acute kidney injury.35
Moreover, specific guidelines for the use of anti-
hyperglycaemic drugs are lacking, mainly because patients
with cirrhosis are excluded from clinical trials,36 leaving insulin
as the only completely safe treatment in cirrhotic patients
regardless of the stage of liver disease. Oral agents can be used
with caution in patients with Child-Pugh class A or B. In partic-
ular, metformin can be considered as first-line therapy, followed
by any of the other therapeutic options, based on the type and
extent of DM and the aetiology of liver disease. Patients with
NAFLD-related cirrhosis may benefit from thiazolidinediones,
glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and
possibly dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-
glucose co-transporter-2 (SGLT2) inhibitors. However, caution
should be taken and potential dose reductions evaluated,
particularly for sulfonylureas or thiazolidinediones, as they are
metabolised by the liver and their impact on disease progression
is still unknown.35,37 Conversely, in patients with Child-Pugh
class C, the use of non-insulin agents should be avoided and
insulin remains the only safe treatment option (Table 1).35
After LT, the prevalence of DM ranges between 31% and 38%,
whereas the prevalence of new-onset DM ranges between 13%
and 28% in the first 3 years after surgery.38
DM severely affects the prognosis of LT recipients, with higher
10-year mortality,39 infection rates and cardiovascular events.40
Given this detrimental effect on post-transplant outcomes,
euglycaemia is a primary goal in post-LT management.41
Male gender,42 ethnicity, family history41 and hepatitis C,43
are well-identified risk factors for the development of post-
transplant DM. Once a diagnosis of DM is established, specific
treatments need to be considered. Lifestyle changes represent
the first-line treatment, but they are often not effective enough
to achieve adequate glycaemic control. Among oral anti-diabetic
drugs, metformin, rosiglitazone, pioglitazone and sulfonylureas
have been studied and established as safe following solid organ
transplantation, either alone or in association with insulin (to
minimise its use).44,45 In the context of patients transplanted for
NAFLD-related cirrhosis, therapeutic strategies effective against
NASH, such as pioglitazone or liraglutide (GLP-1 RAs) may be
preferred.35,46 Recently DPP-4 inhibitors have started to be
routinely used in the setting of solid organ transplantation, with
increasing attention to their adjunctive effect on weight loss.
Nonetheless, the potential effect of DPP-4 inhibitors and GLP-1
RAs on the bioavailability of immunosuppressive drugs has not
been completely clarified. In particular, specific interactions be-
tween sitagliptin and cyclosporine, as well as tacrolimus and
vildagliptin, need to be investigated further.47,48 Lastly, no data
are available for SGLT2 inhibitors (i.e. canagliflozin, dapagliflozin
and empagliflozin) in the post-LT setting, although a recent trialJHEP Reports 2020has suggested that empagliflozin reduces liver fat and improves
alanine aminotransferase levels in patients with type 2 DM and
NAFLD.49 When therapeutic goals are not achieved or symp-
tomatic metabolic decompensation is present, insulin remains
the therapy of choice (Table 2).41Obesity
Obesity and being overweight are virtually constant in patients
with NAFLD. Nearly 95% of patients with morbid obesity (BMI
>40 kg/m2) present with NAFLD,50 and obese patients with
NAFLD are often affected by sarcopenia and myosteatosis, which
can negatively affect waiting list mortality and post-LT out-
comes.51 Moreover, in patients with ESLD, a linear association
has been described between high BMI and high rates of clinical
decompensation, independently of the aetiology of liver dis-
ease.52 Obesity represents a relevant challenge in the LT setting,
as it can make the procedure technically difficult, with poten-
tially high rates of complications.53
Poorer outcomes in obese patients are mainly related to peri-
transplant complications, such as infections and longer intensive
care unit stays, whereas mid-term survival rates are similar to
those of non-obese patients.54 These considerations led to
several transplant centres applying specific BMI thresholds and
weight loss requirements for LT candidates.
When dietary measures and physical exercise are insufficient
for adequate weight loss, some pharmacological options can be
considered. Among these, liraglutide, a GLP-1 RA, appears to be
the most promising as it promotes weight loss as well as
improving NASH. This drug was initially introduced only for its
anti-diabetic properties, but it has recently been approved for
the treatment of obesity in non-diabetic patients.55 In the LEAN
trial, liraglutide was safe and led to resolution of NASH in 39% of
patients (vs. 9% in the placebo group), although no data are
available for patients with NAFLD/NASH-related cirrhosis and
concerns remain as to whether this positive effect is due to
weight loss rather than to the effect of the drug per se. Indeed,
when the treatment arm was compared with the placebo arm,
the reductions in absolute bodyweight (kg) and BMI (kg/m2)
were −5.3 kg vs. −0.6 kg, p = 0.003 and −1.8 vs. −0.3, p = 0.005,
respectively.56 Moreover, adverse gastrointestinal effects of GLP-
1 analogues such as vomiting, diarrhoea and constipation, could
represent an issue for patients with ESLD.
Conversely, orlistat is considered safe and effective in
cirrhotic patients, and may have positive effects on NASH fibrosis
and inflammation.57 In addition to behavioural therapy and ex-
ercise, it was reported to induce an 8% reduction in weight
compared to a 5% reduction with placebo and the same behav-
ioural component. However, high rates of gastrointestinal intol-
erance have been reported.58 Other anti-obesity medications,
such as lorcaserin, phentermine hydrochloric, phentermine/
topiramate (approved only by the FDA) and naltrexone/bupro-
pion, although effective in reducing weight, have not been
investigated in patients with NAFLD, particularly those with
NAFLD-related cirrhosis.59
When morbid obesity is present, and standard interventions
are ineffective, bariatric surgery can be considered, as it has been
shown to lead to weight loss and improve fibrosis.60,61 However,
despite recent encouraging data, there are concerns about the
high decompensation rates when bariatric surgery is performed
on cirrhotic patients with elevated hepatic venous pressure
gradient.623vol. 2 j 100192
Table 1. Management of patients with NAFLD before liver transplantation.
Condition Recommendations
Diabetes mellitus  OGTT is the gold standard for diagnosis of diabetes mellitus.
 HbA1c if used should be associated to continuous blood glucose monitoring.
 Adequate glycaemic control should be achieved.
 Careful assessment of severity of liver disease is mandatory to identify the best therapeutic approach.
Nutritional status  Assessment of nutritional status is mandatory before LT.
 For obese patients, lifestyle modification represents the first-line intervention.
 Healthy diet should be promoted according to indication shown in Figure 2.
 Physical exercise should focus on preservation of residual motility. Caution should be taken in malnourished
and sarcopenic patients to avoid increase of catabolism and muscle loss.
 In obese patients not responding to diet and physical exercise pharmacological therapy or bariatric surgery
can be carefully considered.
Cardiovascular disease  Pre-LT cardiovascular risk stratification is mandatory.
 Specific algorithm of cardiac work-up should be followed as shown in Fig. 1.
Kidney dysfunction  Kidney function should be adequately monitored before LT.
 Combined liver-kidney transplantation should be reserved for patients according to internationally recognised indications.
Malignancies  Screening for pre-LT malignancies should follow the same protocols applied to patients with no-NAFLD related cirrhosis.
 Particular attention should be paid to the gastrointestinal tract and genital system.
HbA1c, glycated haemoglobin; LT, liver transplant; NAFLD, non-alcoholic fatty liver disease; OGTT, oral glucose tolerance test.
Table 2. Management of patients with NAFLD after liver transplantation.
Condition Recommendations
Diabetes mellitus  Immunosuppressive drug modulation is recommended including early tapering of steroids, and minimisation of
CNIs by adding anti-metabolites or mTORi.
 The use of oral anti-diabetic drugs such as metformin, rosiglitazone, pioglitazone and sulfonylureas can be considered
alone or in association with insulin to minimise its use.
 GLP-1 RAs and DPP-4 inhibitors are now routinely used in solid organ transplanted patients; however, attention
must be paid to their interactions with immunosuppressive therapy.
 In patients not achieving therapeutic goals, insulin remains the therapy of choice.
Obesity  Lifestyle modification should include healthy diet and regular mild to moderate physical activity.
 No data are available on pharmacological treatments in the post-LT setting.
 When lifestyle modifications are not effective bariatric surgery can be considered, with sleeve gastrectomy preferred
to Roux-en-Y gastric bypass.
 Endoscopic bariatric therapy is a potential new approach for obese patients after LT.
Dyslipidaemia  Lifestyle modification is the first-line treatment, although this condition is usually refractory to dietary interventions.
 In patients not responding to lifestyle modifications, statins represent the first-line option.
 Attention should be paid to interactions between statins and immunosuppressive drugs.
 Fibrates can be considered when statins are not tolerated.
 Attention should be paid to the development of myopathy.
 Omega-3 fish oil can be beneficial for isolated post-LT hypertriglyceridaemia.
Arterial hypertension  Lifestyle modification, such as low-sodium diet and cessation of smoking, is the first-line treatment.
 Modulation of immunosuppressive therapy is necessary with minimisation of CNIs by adding anti-metabolites or mTORi.
 In patients without proteinuria, dihydropyridine calcium channel blockers represent the first choice.
 Otherwise ACE inhibitors or angiotensin II receptor blockers can be considered.
 Beta-blockers find their primary indication when heart decompensation or arrhythmia are present.
Cardiovascular disease  Patients with specific risk factors, such as age >55 years old, male sex, diabetes mellitus and kidney failure, should
be adequately monitored in the post-LT period.
 In patients presenting specific risk factors, a cardiovascular follow-up with echocardiography at 6, 12, and 24 months
after LT can be suggested.
Kidney dysfunction  In patients presenting with CKD at LT, immunosuppressive minimisation strategies should be used, alongside
interventions to prevent/treat metabolic complications, such as diabetes and hypertension.
ACE, angiotensin-converting enzyme; CKD, chronic kidney disease; CNI, calcineurin inhibitors; DPP-4, dipeptidyl peptidase-4; GLP1 RAs, glucagon-like peptide-1 receptor
agonists; LT, liver transplant; mTORi, mammalian target of rapamycin inhibitors.
ReviewBariatric surgery – performed after or at the same time as LT –
has been confined to isolated experiences and case series.
Among these, in 2018, 3-year outcomes in 13 patients who un-
derwent LT and simultaneous sleeve gastrectomy were reportedJHEP Reports 2020and compared with 36 patients who underwent standard weight
loss intervention. At 3 years after LT, patients treated with LT +
sleeve gastrectomy maintained a significantly higher percentage
of total body weight loss compared with the control group4vol. 2 j 100192
(34.8 ± 17.3% vs. 3.9 ± 13.3%; p <0.001), with a lower prevalence of
hypertension, insulin resistance, and hepatic steatosis at last
follow-up (Table 1).63
After LT, weight gain tends to increase progressively over
time, with reported obesity rates of 33.7% and 40.3% at 1- and
5-years post-transplant, respectively.64 Identified risk factors for
post-LT obesity include age >50 years, pre-LT obesity and NASH
as the indication for LT.65
Appropriate counselling before and immediately after LT is
important to prevent post-transplant obesity and its related
complications, such as the development of DM, graft steatosis,
and de novo malignancies. Lifestyle modifications and a low-
calorie diet represent the cornerstone of weight gain preven-
tion after LT. Moreover, supervised physical activity is considered
safe after LT in stable patients66 and effective for glucose ho-
meostasis,67 which could be particularly beneficial in patients
transplanted for NAFLD/NASH-related liver disease.
Pharmacological therapy can also be considered, although no
data are available in the post-LT setting for liraglutide and no
significant weight loss has been shown for orlistat.68
When indicated, bariatric surgery can be a therapeutic option;
however, only small and heterogeneous case series have been
published to date. All the studies reported effective weight loss,
ranging between 21% and 75%, but with a high rate of mild-
severe complications (30%–40%) and a mortality rate of 20%
when gastric by-pass was performed.69
In the setting of LT, sleeve gastrectomy is always preferable to
Roux-en-Y gastric bypass, not only because of concerns related to
potential malabsorption of immunosuppressive drugs, but also
the inaccessibility of the gastric remnant in case of gastric
bleeding or if endoscopic access to the biliary tree is required.69
More recently endoscopic bariatric therapy has emerged as a
potential approach for obese patients with NAFLD. This includes
gastric and duodenal devices and techniques such as intragastric
balloons, endoscopic sleeve gastroplasty, endoscopic small bowel
by-pass and duodenal mucosal resurfacing, although the latter
could interfere with adsorption of immunosuppressive drugs.
Available data suggest that intragastric balloons induce rapid
weight loss, leading to improvements in NAFLD parameters at
least in the short-term, whereas endoscopic sleeve gastroplasty
leads to stable excess body weight loss, and can therefore
represent a long-term therapeutic option (Table 2).70
To date, no data are available for cirrhotic and transplanted
patients, however we believe this might represent an effective
strategy, especially in the post-transplant setting, although
further investigations are needed.
Arterial hypertension
Arterial hypertension is present in 30%–50% of patients after LT,
with prevalence rates of nearly 70% over long-term follow-up.71
The aetiology of post-LT hypertension is related not only to post-
LT haemodynamic changes, but also to the use of immunosup-
pressive therapy, in particular calcineurin inhibitors (CNIs).
Reducing the use of immunosuppressive drugs, as well as life-
style modifications such as reducing sodium intake and stopping
smoking, represent the first-line therapy to decrease the risk of
arterial hypertension. However, specific pharmacological therapy
is often necessary to reach a blood pressure target of <130/80
mmHg.72 Dihydropyridine calcium channel blockers represent
the first choice, when patients do not exhibit proteinuria,73
otherwise, angiotensin-converting enzyme inhibitors or angio-
tensin II receptor blockers can be considered.73 Beta-blockers areJHEP Reports 2020indicated when heart decompensation or arrhythmia are pre-
sent,74 whereas diuretic therapy is specifically indicated when
volume overload exists (Table 2).75Dyslipidaemia
Dyslipidaemia is common in the post-LT setting, with a preva-
lence rate ranging between 45% and 71% according to criteria
used for its diagnosis.76 Particularly, hypertriglyceridaemia is
more frequent in the early period, whereas hypercholesterolemia
seems to increase later, with 30% of patients presenting with
elevated cholesterol levels 1 year after LT.76 Immunosuppressive
therapy and recipient characteristics, such as DM, obesity and
genetic predispositions, represent the principal determinants of
post-LT dyslipidaemia.77
Compared to the pre-transplant setting, dyslipidaemia
developing after LT is usually refractory to dietary interventions,
so a pharmacological approach is used more frequently. The
European Society of Cardiology recently recommend very
restrictive goals for the management of dyslipidaemia in solid
organ transplanted patients, based on the same targets recom-
mended for patients at high and very high cardiovascular risk.78
When a pharmacological therapy is necessary, statins are
considered the first-line option in liver transplant recipients,
although possible interactions with immunosuppressive therapy
must be carefully monitored.79 Specifically, systemic exposure to
statins may be increased in patients treated with cyclosporin,
increasing the risk of myopathy. Conversely, despite tacrolimus
also being metabolised by CYP3A4, it seems to interact less with
statins than cyclosporin. Among the statins, fluvastatin, pravas-
tatin, pitavastatin and rosuvastatin are metabolised through
different CYP enzymes than the others and are therefore asso-
ciated with fewer pharmacological interactions.80
Ezetimibe may be considered in recipients who do not
tolerate statins,81 whereas the use of fibrates, although well
tolerated, should be strictly monitored based on the potential
development of myopathy.82 Patients with isolated post-LT
hypertriglyceridaemia can benefit from omega-3 fish oil, which
has few drug-drug interactions and some pleiotropic effects,
including anti-inflammatory properties, which might be partic-
ularly beneficial in patients transplanted for NASH-related liver
disease (Table 2).83Cardiovascular disease
Patients with NAFLD-related cirrhosis present specific metabolic
and cardiovascular alterations that need to be properly assessed
both during the LT evaluation, as they could represent an abso-
lute or relative contraindication to LT, and after LT, as they are
one of the major causes of death in the post-LT period.
Patients with NAFLD are at higher risk of cardiovascular
events compared to those without NAFLD (odds ratio [OR] 1.64,
95% CI 1.26–2.13), and the risk doubles when considering more
severe NAFLD or NASH (OR 2.58; 95% CI 1.78–3.75).84 In patients
with ESLD, severe peripheral vasodilatation can mask myocardial
dysfunction, so-called cirrhotic cardiomyopathy, rendering
pre-LT cardiovascular risk stratification difficult. This population
not only exhibits morphological or kinetic cardiac alterations, but
frequently also QTc interval prolongation,85 increasing the risk of
ventricular arrhythmia86 when DM is present.87 Obstructive
sleep apnoea and its cardiopulmonary-related complications also
need to be considered, since they can increase the surgical risk
during LT.885vol. 2 j 100192
Past medical hystory, clinical examination, peripheral
artery oxygen saturation, 12 lead electrocardiogram and
a complete transthoracic ultrasound with assessment of
left ventricular, right ventricular and valvular function (with
an estimation of systolic pulmonary artery pressure)
If positive first level or
patients >50 years old or
more than 2 cardiovascular 
risk factors:
Dobutamine stress
echocardiogram (DSE)
(or equivalent)
Positive DSE
independently
from clinical
suspicion and
moderate/high
clinical suspition
and  DSE non
diagnostic
Coronary
angiography
Moderate/high
clinical suspicion
and DSE negative
Coronary CT or
nuclear medicine or 
additional CV test
Low clinical
suspicion and
DSE negative
If negative first level:
no further investigations
Right heart
catheterization
If suspicion of pulmonary
hypertension or high
estimated systolic 
pulmonary artery pressure
+ -
First level
Second level
Third level
Fig. 1. Cardiac work-up algorithm in the evaluation of patients with non-alcoholic fatty liver disease before liver transplantation.
ReviewIn patients undergoing evaluation for LT, the first level of
cardiac assessments (i.e. history and clinical examination, elec-
trocardiogram and a complete transthoracic ultrasound) should
be followed by second-line examinations according to the spe-
cific cardiovascular risk stratification (Fig. 1). In patients >50
years old or with >−2 cardiovascular risk factors (i.e. arterial hy-
pertension, obesity, dyslipidaemia, diabetes), non-invasive stress
testing (e.g. dobutamine stress echography or nuclear perfusion
stress testing) should be performed.89,90 However, non-invasive
functional testing has limited predictive value for obstructive
coronary artery disease in patients with cirrhosis, in whom the
sensitivity and specificity of dobutamine stress echocardiogra-
phy are reduced.91,92
Although coronary angiography is considered the gold stan-
dard, studies performed in LT candidates are not completely
conclusive,93,94 making it difficult to predict the real impact of
pre-LT asymptomatic cardiovascular abnormalities on long-term
outcomes. However, a recent study has shown that pre-
transplant coronary artery disease, when adequately treated,
may not affect post-LT survival.95 Moreover, the use of statins in
the post-transplant period might confer a survival benefit (haz-
ard ratio [HR] 0.25; 95% CI 0.12–0.49; p <0.001), independently of
the use of aspirin.95
An adequate pre-LT cardiovascular risk assessment is there-
fore crucial to stratify patients according to their probability of
developing cardiovascular events after LT, enabling rapid diag-
nosis and optimal management. For this purpose, the use of the
Framingham Risk Score (an algorithm to predict cardiovascular
risk at 10 years based on age, sex, smoking, DM, arterial hyper-
tension, and dyslipidaemia) has been proposed to predictJHEP Reports 2020cardiovascular risk after LT, and to tailor diagnostic tests and
therapeutic strategies according to the risk score.96 More
recently the CAR-OLT risk score (Cardiovascular Risk in Ortho-
topic Liver Transplantation) has been validated in the United
States population. This score includes preoperative recipient
variables such as age, sex, race, employment status, education
status, history of HCC, diabetes, heart failure, atrial fibrillation,
pulmonary or systemic hypertension, and respiratory failure.
While solid recommendations cannot be made, it might be
routinely applied to identify candidates who deserve further
cardiological investigations, based on its discriminative perfor-
mance (C statistic = 0.78, bias-corrected C statistic = 0.77), which
is better than published risk models, and its easy availability.97
Moreover, because of the possibility of misdiagnosing cirrhotic
cardiomyopathy, which may affect post-LT outcome, 6-monthly
echocardiography has been proposed for patients with any de-
gree of systolic/diastolic dysfunction on the LT waiting list,
irrespective of liver disease aetiology.98 Further strategies
include coronary CT angiography or cardiac MR as functional
non-invasive tests to diagnose cardiac abnormalities. A preop-
erative coronary calcium score of >400 was found to predict
cardiovascular events 1 year after LT,99 suggesting a possible role
of coronary calcium scores in pre-surgical assessment. Despite
concerns related to radiation exposure (for CT), lack of validation
in the LT setting and cost, these techniques represent a very
promising alternative for the study of pre-LT cardiac dysfunction.
After LT, patients with NASH present a significantly higher
risk of death from cardiovascular complications than patients
transplanted for other aetiologies, as shown by a recent meta-
analysis.98 Interestingly, the incidence of post-transplant6vol. 2 j 100192
cardiovascular events seems significantly increased in the first
year after transplant, as reported by VanWagner et al.,100 who
observed an increase in cardiovascular-related 1-year mortality
after LT in patients with NAFLD vs. patients transplanted for
alcohol-related liver disease (26% vs. 8%). This difference was also
evident after controlling for potential confounding factors such
as age, sex, smoking habit, pre-transplant diabetes, cardiovas-
cular disease, and the presence of metabolic syndrome.
The most common cardiovascular events developing post-LT
in patients with NAFLD/NASH are acute pulmonary oedema
(18%), new onset atrial fibrillation (10%) and sudden cardiac ar-
rest (8%).100 In particular, the development of atrial fibrillation
after LT can increase the risk of thromboembolism, representing
an independent risk factor for post-transplant mortality.101
In a recent retrospective study, the authors reported a car-
diovascular event rate of approximately 40% at 5 years after LT in
patients with underlying NASH compared to 5% to 10% in non-
NASH recipients. In this cohort, cardiovascular disease was
defined as coronary artery disease, myocardial infarction, cardiac
arrest, systolic or diastolic heart failure, arrhythmia, stroke,
transient ischaemic attack, and symptomatic peripheral vascular
disease.24
Specific risk factors have been associated with post-LT car-
diovascular mortality, such as age >55 years old, male sex, DM,
and kidney failure100; therefore, a strict cardiovascular follow-up
should be performed with echocardiography at 6, 12, and 24
months after LT in patients with any of these risk factors
(Table 2).98Other medical complications
Kidney dysfunction
Additional risk factors are often present in patients with NAFLD/
NASH and represent additional issues in the evaluation for LT and
management after LT. Amongst these, chronic kidney disease
(CKD) is one of the most critical,102 as a recent study has esti-
mated that pre-LT CKD is significantly and independently asso-
ciated with post-LT mortality (HR 1.16, p <0.001).103 Moreover, it
has been demonstrated that NASH is an independent predictor of
CKD stage >−3 after LT (Tables 1 and 2).
104
A recent study based on the UNOS database showed that
NAFLD/NASH-cirrhosis is the most rapidly growing indication for
simultaneous liver-kidney transplant in the United States. Five-
year liver graft survival rates were comparable between pa-
tients with NASH and patients transplanted for other non-viral
indications (78% vs. 74%, p = 0.14), whereas kidney graft
outcome was 1.5-fold inferior.105
While combined liver-kidney transplantation should be
reserved for those patients who fulfil the internationally recog-
nised criteria,106 specific strategies in post-LT management
should be reserved for patients with NASH who present with
CKD at LT. These should mainly focus on immunosuppressive
minimisation strategies, as well as the prevention or treatment
of metabolic complications, such as diabetes and hypertension,
which could further worsen renal function in the post-transplant
period.
Malignancies
NAFLD is also associated with an increase in the risk of devel-
oping gastrointestinal tumours (stomach: incidence rate ratio
[IRR] = 2.3; 95% CI 1.3–4.1, colon: IRR = 1.8; 95% CI 1.1–2.8) and
uterine cancer (IRR = 2.3; 95% CI 1.4–4.1), as demonstrated in aJHEP Reports 2020recent longitudinal-study on a large cohort of patients with
NAFLD.107 Interestingly, when NAFLD is not present, obesity and
cancer are less associated, suggesting that NAFLD could increase
the carcinogenetic effect of obesity. Although these data alone do
not allow for any systematic recommendations, they highlight
the importance of a complete and thorough evaluation of pa-
tients with NAFLD/NASH, especially if they are potential candi-
dates for LT (Table 1).Nutrition and physical exercise
Nutritional status assessment needs to be considered as part of
the standard pre-LT evaluation in patients with NAFLD-related
cirrhosis. This should focus not only on the identification of
sarcopenic and malnourished patients but also on obese patients
for whom the effect of >−10% weight loss on liver fat and
inflammation is well-established (Table 1).108
Similarly after LT, given the high risk of developing metabolic
complications, a multidisciplinary approach is mandatory to
promote lifestyle modifications, such as a balanced diet and
adequate physical activity, starting in the early post-LT period.109
Dietary advice, based on large cohort-population studies and
on patients with NAFLD/NASH,110 consists of the choice of a
Mediterranean diet, preferring extra virgin olive oil111 to
trans-fat foods, avoiding processed meats and increasing the
consumption of fish rich in omega 3-fatty acids.112 Coffee con-
sumption above 2 cups per day has proven to be effective in
decreasing fibrosis in patients with NASH,113 although data on
ESLD and in the post-LT setting are scarce (Fig. 2).
Considering physical activity, it has been shown that in pa-
tients listed for LT, maximal exercise capacity predicts 90-day
post-transplant mortality114; it is therefore paramount to try to
preserve as much residual motility as possible.
Physical activity has been proven to be beneficial and safe
even in patients with moderately advanced portal hyperten-
sion,115 although LT candidates are often too sick to safely
perform physical activities.
A pilot-study of 8 patients awaiting LT (mean Child Pugh
score, 7 ± 3) showed that an adapted physical activity pro-
gramme (cycloergometry and muscle strengthening) for 12
weeks might be feasible and effective. The authors recorded an
increase in VO2 peak values (21.5 ± 5.9 m/kg per min vs. 23.2 ±
5.9 ml/kg; p <0.008), with an improvement in all parameters
evaluated: maximum power (p = 0.02), 6-min walk distance
(p <0.02), muscle strength (p = 0.008), respiratory threshold
power (p = 0.02), and quality of life scale (36% ± 4% to 39% ± 3%)
compared to baseline.116
In a recent review and meta-analysis117 based on 4 rando-
mised controlled trials, including 81 patients, physical activity
was not associated with severe adverse events, or worsening of
liver function (measured by Child-Pugh and model for end-stage
liver disease scores). Moreover, a significant reduction in HVPG
in the treatment group was observed in a single study (mean
difference −2.5 mmHg; 95% CI −4.76 to −0.24; p = 0.03).
Although data on patients with compensated cirrhosis are
reassuring in confirming the effectiveness and safety of a com-
bination of hypocaloric-normoproteic diet and moderate super-
vised physical activity,115 only few data exist in decompensated
patients.
Moreover, it is important to note that exercise performed by
malnourished and sarcopenic patients may be deleterious,
leading to increased catabolism and muscle loss.118 The European7vol. 2 j 100192
Every meal
Daily
Weekly
Vegetables
• More than 2
  vegetables.
• Variety of coulor and
  seasonality preferred.
Whole  grain
• 1-2 portions of whole
  grains (like pasta,
  bread, brown rice and
  other cereals)
• Diabetic patients
  should limit at 1
  per/day.
• Limit the use of
  refined grains.
Fruits
• 1-2 fruits
• Diabetic patients
  should preferred less
  naturally sugary fruits.
Dairy products
• 1-2 portions
  per/day (like yoghurt,
  milk, cheese)
• Low-fat products
  preferred.
Healthy proteins
• 1 portion per/day
  varying between fish,
  poultry or white
  meat, beans, eggs
  and nuts.
Red meat
• Less than 2 portions per
  week
• Avoid bacon, cold cuts,
  sausages and processed 
  meat
Cake and pastries
• Less than 1 portion per
  week
• Should be avoided by
  obese patients
•    Use healthy oils, like olive oil, for cooking or on salad. Limit butter and avoid trans-fats.
•    Drink preferentially water according to clinical indication, when fluid restriction is
     prescribed. Avoid all kind of sugary beverages and alcohol.
•    Limit the use of salt on food. Eventually use onions, garlic or spices to flavour the food.
•    When other comorbidities may be present (i.e. diabetes or overweight/obesity), specific
     dietary adjustments can be required.
•    Specific counseling can be required to address barriers towards a healthy diet.
•    Drink coffee with moderation (2 cups per day)
•    Split food intake into 3 main meals (breakfast, lunch and dinner) and 3
     snacks (mid-morning, mid-afternoon, late evening). The late-evening
     snack is the most important and adding an amount of protein is advisible
•   Stay active. Regular physical activity
    according to clinical condition, either
    aerobic  or not, at least two times per
    week.
Fig. 2. Practical dietary advice for patients with non-alcoholic steatohepatitis-related advanced liver disease according to the Mediterranean diet.
ReviewClinical Practice Guidelines on nutrition in chronic liver
disease suggests adopting screening tools like the “Royal Free
Hospital-nutritional prioritizing tool” in patients with normal
BMI. When malnutrition is diagnosed, a thorough evaluation and
consequent interventions need to be put in place.119
Three randomised controlled trials demonstrated that struc-
tured exercise training initiated early after LT improves re-
cipients’ exercise capacity and physical function,120–122 although
it is not yet known if the identified improvements are main-
tained in the long-term after completing the exercise
programme.123
Moreover, despite the lack of well-designed randomised
controlled trials, it is well-known that better quality of life is
reported in patients who are physically active in the post-
transplant period.120,124,125Pharmacological therapy for NASH
To date, several new pharmacological therapies have been tested
for NASH, although the majority have not received regulatory
approved nor been evaluated in advanced liver disease. In pa-
tients without DM, the use of vitamin E can be considered. In
patients with NASH-related cirrhosis, Vilar-Gomez et al.126 re-
ported higher transplant-free survival rates (78% vs. 49%, p <0.01)
and lower rates of hepatic decompensation (37% vs. 62%, p =
0.04) in patients treated with vitamin E compared to those who
did not receive this therapy. However, concerns exist about the
safety of vitamin E supplementation, based on reports of anJHEP Reports 2020increased risk of haemorrhagic stroke and prostate cancer, as
well as controversial data on increased overall mortality.127–130
In the setting of LT, where advanced or decompensated liver
disease is prevalent, the principal goal of these therapies should
be to counteract the natural history of the disease, rather than
the regression of inflammation and fibrosis. However, most of
these therapies are being tested in phase IIb/III trials in patients
with NASH-related mild to moderate liver disease. Moreover, the
endpoints are not homogeneously defined, making it difficult to
perform comparisons in terms of effectiveness. Recently, emri-
casanwas tested in a multicentre randomised placebo-controlled
trial in patients with NASH-related ESLD and severe portal
hypertension; unfortunately the results were negative.131
Conversely, obeticholic acid has been shown to be effective in
improving fibrosis in patients with NASH and fibrosis stages
F2-F3 or F1, although concerns still exist in patients with
advanced liver disease.132Management of immunosuppressive therapy
In patients transplanted for NAFLD/NASH-related cirrhosis,
immunosuppressive protocols need to be optimised in order to
minimise the risk of metabolic complications. This is essential
not only to reduce the cardiovascular risk, but also to decrease
the risk of developing graft steatosis, and consequently NAFLD/
NASH recurrence (Table 2).133
DM is mainly affected by corticosteroid therapy, which is
usually used early post-LT, and by tacrolimus. Although8vol. 2 j 100192
tacrolimus and cyclosporine share the same mechanism of
damage, acting directly on pancreatic islets, the risk of devel-
oping or worsening DM is significantly higher with tacrolimus
than with cyclosporine (relative risk 1.38, 95% CI 1.01–1.86).134
Therefore, in patients with DM, steroids should be withdrawn
early after LT and immunosuppressive protocols which include
minimising the tacrolimus dose should be preferred.
Concerning obesity, besides applying the same concepts as for
patients with DM, a post hoc analysis of a previous trial designed
to investigate the effect of everolimus on post-LT renal func-
tion135 showed that the early use of everolimus plus lower dose
tacrolimus was associated with a weight reduction (although
modest) at 1 and 2 years after LT.136
Arterial hypertension, hyperlipidaemia and hypertrigly-
ceridaemia are mainly affected by the use of CNIs, with cyclo-
sporine conferring a higher risk of these side effects than
tacrolimus.137 Similarly, mammalian target of rapamycin in-
hibitors (mTORi) act on dyslipidaemia, particularly hyper-
triglyceridaemia.38 Therefore, patients with arterial hypertension
and/or dyslipidaemia should be treated with immunosuppres-
sive minimisation protocols and mTORi should be avoided.137,138
Although the relationship between cardiovascular events and
immunosuppression has not been well established, tailoring
immunosuppression to the patient’s specific metabolic risk
profile can be used to prevent post-LT cardiovascular morbidity.JHEP Reports 2020Moreover, since major cardiac events can be affected by post-LT
renal impairment135 minimising CNI exposure is paramount, not
only to spare kidney function, but also to indirectly reduce car-
diovascular morbidity. Therefore, immunosuppression protocols
based on mTORi or antimetabolites in association with reduced
doses of tacrolimus, or tacrolimus withdrawal when feasible, can
be considered an effective immunosuppressive strategy for
patients transplanted for NASH-related cirrhosis.139Conclusion
NAFLD/NASH-related cirrhosis is becoming one of the leading
indications for LT in Western countries. Special issues in the pre-
transplant work-up and post-transplant management need to be
addressed to improve outcomes in these patients. Although
short- and mid-term survival rates are comparable to those of
patients transplanted for other indications, NAFLD/NASH re-
cipients present higher post-transplant incidence of infections
and cardiovascular events. Lifestyle modifications, which can
counteract obesity and metabolic complications in both pre- and
post-LT, as well as tailored use of immunosuppressive therapy
remain the cornerstone of clinical management. Further pro-
spective, longitudinal studies are needed to adequately highlight
specific recommendations in order to achieve the best results for
patients with NAFLD/NASH before and after LT.Abbreviations
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